Electrophysiological features and prognosis of peripheral neuropathy associated with IgM monoclonal gammopathy: a single-center analysis in South Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Clinical spectrum of immunoglobulin M (IgM) monoclonal gammopathy varies from IgM monoclonal gammopathy of unknown significance (IgM-MGUS) to hematological malignancies. We evaluated the clinical features, electrophysiological characteristics, and prognosis of patients with peripheral neuropathy associated with IgM monoclonal gammopathy (PN-IgM MG). Methods: We retrospectively evaluated 25 patients with PN-IgM MG. Peripheral neuropathy was classified as axonal, demyelinating, or undetermined, based on electrophysiological studies. We classified the enrolled patients into the IgM-MGUS and malignancy groups, and compared the clinical and electrophysiological features between the groups. Results: Fifteen patients had IgM-MGUS and 10 had hematologic malignancies (Waldenström’s macroglobulinemia: two and B-cell non-Hodgkin’s lymphoma: eight). In the electrophysiological evaluation, the nerve conduction study (NCS) criteria for demyelination were met in 86.7% of the IgM-MGUS group and 10.0% of the malignancy group. In particular, the distal latencies of the motor NCS in the IgM-MGUS group were significantly prolonged compared to those in the malignancy group (median, 9.1 ± 5.1 [IgM-MGUS], 4.2 ± 1.3 [malignancy], p = 0.003; ulnar, 5.4 ± 1.9 [IgM-MGUS], 2.9 ± 0.9 [malignancy], p = 0.001; fibular, 9.3 ± 5.1 [IgM-MGUS], 3.8 ± 0.3 [malignancy], p = 0.01; P-posterior tibial, 8.3 ± 5.4 [IgM-MGUS], 4.4 ± 1.0 [malignancy], p = 0.04). Overall treatment responses were significantly worse in the malignancy group than in the IgM-MGUS group (p = 0.004), and the modified Rankin Scale score at the last visit was higher in the malignancy group than in the IgM-MGUS group (2.0 ± 1.1 [IgM-MGUS], 4.2 ± 1.7 [malignancy], p = 0.001), although there was no significant difference at the initial assessment. Conclusions: The risk of hematological malignancy should be carefully assessed in patients with PN-IgM MG without electrophysiological demyelination features.
Abstract
Background: Clinical spectrum of immunoglobulin M (IgM) monoclonal gammopathy varies from IgM monoclonal gammopathy of unknown significance (IgM-MGUS) to hematological malignancies. We evaluated the clinical features, electrophysiological characteristics, and prognosis of patients with peripheral neuropathy associated with IgM monoclonal gammopathy (PN-IgM MG). Methods: We retrospectively evaluated 25 patients with PN-IgM MG. Peripheral neuropathy was classified as axonal, demyelinating, or undetermined, based on electrophysiological studies. We classified the enrolled patients into the IgM-MGUS and malignancy groups, and compared the clinical and electrophysiological features between the groups. Results: Fifteen patients had IgM-MGUS and 10 had hematologic malignancies (Waldenström’s macroglobulinemia: two and B-cell non-Hodgkin’s lymphoma: eight). In the electrophysiological evaluation, the nerve conduction study (NCS) criteria for demyelination were met in 86.7% of the IgM-MGUS group and 10.0% of the malignancy group. In particular, the distal latencies of the motor NCS in the IgM-MGUS group were significantly prolonged compared to those in the malignancy group (median, 9.1 ± 5.1 [IgM-MGUS], 4.2 ± 1.3 [malignancy], p = 0.003; ulnar, 5.4 ± 1.9 [IgM-MGUS], 2.9 ± 0.9 [malignancy], p = 0.001; fibular, 9.3 ± 5.1 [IgM-MGUS], 3.8 ± 0.3 [malignancy], p = 0.01; P-posterior tibial, 8.3 ± 5.4 [IgM-MGUS], 4.4 ± 1.0 [malignancy], p = 0.04). Overall treatment responses were significantly worse in the malignancy group than in the IgM-MGUS group (p = 0.004), and the modified Rankin Scale score at the last visit was higher in the malignancy group than in the IgM-MGUS group (2.0 ± 1.1 [IgM-MGUS], 4.2 ± 1.7 [malignancy], p = 0.001), although there was no significant difference at the initial assessment. Conclusions: The risk of hematological malignancy should be carefully assessed in patients with PN-IgM MG without electrophysiological demyelination features.
참고문헌 (15)
- Kyle RA, "The spectrum of IgM monoclonal gammopathy in 430 cases", Mayo Clin Proc, 62, pp.719~731 (1987)
- Cao XX, "The clinical spectrum of IgM monoclonal gammopathy : a single center retrospective study of 377 patients", Leuk Res, 46, pp.85~88 (2016)
- Chassande B, "Peripheral neuropathy associated with IgM monoclonal gammopathy : correlations between M-protein antibody activity and clinical", electrophysiological features in 40cases, 1998, pp.21, 55~62
- Chaudhry HM, "Monoclonal gammopathy-associated peripheral neuropathy : diagnosis and management", Mayo Clin Proc, 92, pp.838~850 (2017)
- Ramchandren S, "Monoclonal gammopathy and neuropathy", Curr Opin Neurol, 22, pp.480~485 (2009)
- Levine T, "Peripheral neuropathies in Waldenström’s macroglobulinaemia", J Neurol Neurosurg Psychiatry, 77, pp.224~228 (2006)
- Klein CJ, "The neuropathies of Waldenström’s macroglobulinemia(WM)and IgM-MGUS", Can J Neurol Sci, 38, pp.289~295 (2011)
- 김지은, "말초신경병증의 임상 척도 – 2021년 개정판", 대한신경과학회지, 39, pp.2~14 (2021), 대한신경과학회
- Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy(CIDP), "Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force", Neurology, 41, pp.617~618 (1991)
- Shahani BT, "Terminal latency index (TLI) and late response studies in motor neuron disease (MND), peripheral neuropathies and entrapment syndromes", Acta Neurol Scand, 60, pp.118~ (1979)
- Delmont E, "Multifocal motor neuropathy with and without conduction block: a single entity?", Neurology, 67, pp.592~596 (2006)
- Silberman J, "Review of peripheral neuropathy in plasma cell disorders", Hematol Oncol, 26, pp.55~65 (2008)
- Jalali S, "Progression from monoclonal gammopathy of undetermined significance of the immunoglobulin M class(IgM-MGUS)to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism", Redox Biol, 41, pp.101927~ (2021)
- Niermeijer JM, "Prognosis of polyneuropathy due to IgM monoclonal gammopathy : a prospective cohort study", Neurology, 74, pp.406~412 (2010)
- McMaster ML, "Prevalence, clinical aspects, and natural history of IgM MGUS", Cytometry B Clin Cytom, 78, pp.S91~S97 (2010)